ImmunityBio (IBRX) Long-Term Debt Issuances (2020 - 2026)

ImmunityBio (IBRX) has 6 years of Long-Term Debt Issuances data on file, last reported at $102.2 million in Q1 2026.

• Quarterly Long-Term Debt Issuances changed N/A year-over-year to $102.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $102.2 million (up 5.44% YoY) and the FY2024 annual result came in at $97.0 million, down 62.52% from the prior year.
• Long-Term Debt Issuances rose to $102.2 million in Q1 2026 per IBRX's latest filing, from $97.0 million in the prior quarter.
• Across five years, Long-Term Debt Issuances topped out at $199.0 million in Q3 2023 and bottomed at $29.9 million in Q1 2023.
• The 4-year median for Long-Term Debt Issuances is $102.2 million (2026), against an average of $113.5 million.
• The widest annual swing landed in 2022, when Long-Term Debt Issuances plunged 83.33%; it then surged 286.95% in 2023.
• Tracing IBRX's Long-Term Debt Issuances over 4 years: stood at $49.8 million in 2022, then surged by 286.95% to $192.5 million in 2023, then tumbled by 49.64% to $97.0 million in 2024, then grew by 5.44% to $102.2 million in 2026.
• Per Business Quant, the three latest IBRX Long-Term Debt Issuances figures stand at $102.2 million (Q1 2026), $97.0 million (Q2 2024), and $192.5 million (Q4 2023).

Peer Comparison